Clinical trials: Chimeric Antigen Receptor T-cell Therapy
Acute Lymphoblastic Leukemia
Long-Term Follow-up Study for Patients Previously Treated With JCAR015
This study will provide long-term follow-up for patients who have received treatment with JCAR015 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of JCAR015 for…
- Trial name
- NCT02813252
- Testing
- JCAR015
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
B-cell Lymphomas
Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas
Currently, a majority of B cell lymphomas cannot be cured by standard chemo-radiotherapy. Most B cell lymphomas express cluster of differentiation antigen 19 (CD19), which represents a very attractive target for chimeric antigen…
- Trial name
- 4SCAR19273 (NCT02247609)
- Testing
- Anti-CD19 CAR T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University
B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
This phase I trial tests safety, side effects and best dose of B-cell activating factor receptor (BAFFR)-based chimeric antigen receptor T-cells, with fludarabine and cyclophosphamide lymphodepletion, for the treatment of…
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT06191887
- Testing
- Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Metastatic Non Small Cell Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma
MOv19-BBz CAR T Cells in FRa+ Cancers
This is a Phase I open-label clinical trial to assess the safety, feasibility, and preliminary efficacy of intrapleural administration of MOv19-BBz CAR T cells in patients with FRa+ cancers.
- Trial name
- NCT07116057
- Testing
- MOv19-BBz CAR T cells, Cyclophosphamide/Fludarabine, FRa Expression Testing
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pennsylvania
Relapsed and Refractory Multiple Myeloma (RRMM)
SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
This is a Phase I, single-center, single-arm, open-label clinical study to evaluate the safety, tolerability, and preliminary efficacy of SL4903 autologous T-cell injection (CAR-T cell therapy) in adult patients with relapsed or…
- Trial name
- SL4903 (NCT07234721)
- Testing
- SL4903 Autologous T-Cell Injection
- Volunteers
- 9 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Solid Tumor, Adult
CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors
In this single-center, single-arm,prospective, open-label, phase 1/2 study, the safety and efficacy of autologous CD70 targeted chimeric antigen receptor modified T (CAR-T) cell therapy will be evaluated in patients with CD70…
- Trial name
- NCT05947487
- Testing
- CD70-targeting CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Hematologic Malignancy, ALL, Childhood
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma.
- Conditions
- Hematologic Malignancy, ALL, Childhood, AML, Childhood, Lymphoma
- Trial name
- NCT06326463
- Testing
- Fludarabine, Cyclophosphamide, CD70-CAR T cell infusion (Autologous)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- St. Jude Children's Research Hospital
Peripheral T Cell Lymphoma
Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma
Despite the use of monoclonal antibodies, checkpoint inhibitors, and bispecific T cell adapters (BiTE) Immunotherapies such as chimeric antigen receptor (CAR) T cells have completely changed the treatment methods of various…
- Trial name
- NCT05979792
- Testing
- CAR-T Therapy
- Where
- 8 sites in China
- Volunteers
- 35 people
- Sponsor
- Zhao Weili
Relapsed/refractory Lymphoma, Relapsed/Refractory Leukemia
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
This study is a single-center, open-label clinical trial of single-dose of CAR T-cells in subjects with relapsed/refractory hematologic malignancy.
- Trial name
- NCT06756321
- Testing
- anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Affiliated Hospital of Nantong University
T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory
Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma
This is a Phase 1, first-in-human (FIH), open-label, multicenter, study of LB1901 administered to adult subjects with histologically confirmed CD4+ relapsed or refractory Peripheral T-cell lymphoma (PTCL) (PTCL not otherwise…
- Conditions
- T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Recurrent
- Trial name
- NCT04712864
- Testing
- LB1901
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Legend Biotech USA Inc
Juvenile Dermatomyositis
Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis
This is a Phase I clinical trial to evaluate the efficacy and safety of CD19-targeted CAR-T in the treatment of refractory juvenile dermatomyositis (RJDM).The experiment was divided into two phases: dose exploration (Part A) and…
- Trial name
- NCT06569472
- Testing
- CD19-targetd CAR-T
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Acute Myeloid Leukemia (AML), Relapsed/Refractory Acute Myeloid Leukemia
CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia
This is a single-center, open-label, single-arm, prospective, investigator-initiated dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an autologous CLL-1/CD70 dual-target CAR-T cell…
- Trial name
- NCT07897136
- Testing
- CLL-1-CD70 CAR-T Cell Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Liping Dou
Relapsed Pediatric ALL, Hematopoietic Cell Transplantation
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
The purpose of this study is to learn more about newer methods of transplanting blood cells donated by a partially matched family member to children with high-risk CD19 positive leukemia ALL.
- Conditions
- Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy
- Trial name
- NCT07257419
- Testing
- Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- St. Jude Children's Research Hospital
Relapsed or Refractory Multiple Myeloma (RRMM)
In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma
This study is an investigator-initiated, single-center, single-arm clinical study with a target population of patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT07715630
- Testing
- Invivo CAR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Multiple Myeloma
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
The purpose of this study is to determine the efficacy and safety of targeted BCMA CART cells secreting PD1 and interleukin 21 fusion protein immunotherapy for first-line consolidation therapy of multiple myeloma with renal…
- Trial name
- NCT07489534
- Testing
- PD-1Ab21-BCMA CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Daihong Liu
B-cell Lymphoma
Clinical Study of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma
To evaluate the CR rate of B-NHL subjects who achieved PR at intermediate assessment after first-line chemotherapy treated with autologous stem cell transplantation + Anti-CD19 CAR T cells.
- Trial name
- NCT05755828
- Testing
- ASCT+CAR-T Cell Infusion
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Leukemia, Lymphoma
Early Integration of Palliative and Supportive Care in Cellular Therapy
Research has shown that early palliative care in cancer care is associated with improved symptom management, better prognostic understanding, improved quality of life for patients and family caregivers, and even improved…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Blood Cancer
- Trial name
- PALS_CT (NCT05190653)
- Testing
- Early palliative and supportive care
- Where
- Canada
- Volunteers
- 152 people
- Sponsor
- Alberta Health Services, Calgary
Patient Reported Outcome Measures, CAR T-Cell Therapy
ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy
This study is designed as a feasibility study implementing electronic Patient Reported Outcomes (ePRO) in CAR T treatment for hematological malignancies, in order to describe AE reporting.
- Trial name
- CARTePRO (NCT05354973)
- Testing
- Consilium CareTM
- Where
- Switzerland
- Volunteers
- 11 people
- Sponsor
- Stiftung Swiss Tumor Institute
B-cell Lymphoma
Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma
This is a single-arm, open-label clinical study evaluating the efficacy and safety of CD20/CD19/CD22 multi-targeted chimeric antigen receptor T-cell (CAR-T) injection in patients with relapsed/refractory B-cell lymphoma.
- Trial name
- NCT07093086
- Testing
- Triple-targeted CAR-T Therapy
- Where
- 2 sites in China
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Ovarian Cancer
Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors
This is a single site, open label, Phase 1 study using a 3 + 3 dose escalation design in two cohorts of adults with recurrent, platinum-resistant ovarian tumors.
- Trial name
- NCT06646627
- Testing
- B7-H3CART
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.